comprehensive -WSS

comprehensive

author：fashion 2025-09-03 12:06:50 - browse：6418

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

knowledge

WSS

California man arrested in connection with serial murders of Mexican strip club workers

Resistance to opioid

Trump seeks lengthy delay of classified docs trial, citing upcoming election

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

How redistricting in 6 states could affect who controls Congress

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Wikipedia

comprehensive

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AMAs digital advisors table RPM coding reform proposal, again

Trump demands the U.S. pay no more for drugs than other countries … again

Sen. Bill Cassidy on how to lower drug prices

Medicare details structure of new drug price negotiation program

Artificial intelligence use in health care faces greater scrutiny in 2024

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Amylyx, Aurinia, and IQVIA

How one medical school became remarkably diverse

Long Covid research funding gets a major boost from NIH

leisure time

Resistance to opioid

Ebola vaccine can save some who are already sick, per new study

Ebola vaccine can save some who are already sick, per new study

Neutralizing antibodies against HIV shows promise in children

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

knowledge

explore

focus

focus